177 related articles for article (PubMed ID: 2512048)
1. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Cabezudo I; Pfaller M; Bale M; Wenzel R
Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
[TBL] [Abstract][Full Text] [Related]
2. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
Canis F; Cavallo JD; Husson MO
Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of cefpirome compared with that of other agents.
Raizes EG; Cantey JR
J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
6.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
7. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
Valdes JM; Baltch AL; Smith RP; Hammer MC; Ritz WJ
J Antimicrob Chemother; 1990 Apr; 25(4):575-84. PubMed ID: 2112539
[TBL] [Abstract][Full Text] [Related]
8. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].
Niitsuma K; Saitoh M; Kojimabara M; Kashiwabara N; Aoki T; Tomizawa M; Maeda J; Kosenda T
Jpn J Antibiot; 2001 Feb; 54(2):79-87. PubMed ID: 11338681
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
Heilesen AM; Permin H; Koch C; Høiby N
Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin.
Marton A; Major P
Microb Drug Resist; 1996; 2(3):361-9. PubMed ID: 9158796
[TBL] [Abstract][Full Text] [Related]
12. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of 100 blood isolates of Pseudomonas aeruginosa to 19 antipseudomonal antibiotics: old and new.
Korvick J; Yu VL; Hilf M
Diagn Microbiol Infect Dis; 1987 Jun; 7(2):107-11. PubMed ID: 3115670
[TBL] [Abstract][Full Text] [Related]
14. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
15. Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
Mintz L; Drew WL
Antimicrob Agents Chemother; 1981 Feb; 19(2):332-4. PubMed ID: 6289731
[TBL] [Abstract][Full Text] [Related]
16. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.
Murray PR
Antimicrob Agents Chemother; 1980 Mar; 17(3):474-6. PubMed ID: 6252830
[TBL] [Abstract][Full Text] [Related]
19. [Activities of antipseudomonal agents against clinical isolates of Pseudomonas aeruginosa].
Murase M; Miyamoto H; Handa T; Saheki S; Takeuchi N
Jpn J Antibiot; 1995 Oct; 48(10):1581-9. PubMed ID: 8544340
[TBL] [Abstract][Full Text] [Related]
20. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
Yamashiro Y; Ogake N; Takahata M; Minami S
Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
